Introduction
Glucuronidation is a key pathway for the metabolism, detoxification and elimination of numerous xenobiotics as well as endogenous compounds such as bilirubin and steroid hormones (Burchell and Coughtrie, 1989; Tukey and Strassburg, 2000; Wells et al., 2004 ).
The glucuronidation reaction, which involves the transfer of the glucuronic acid moiety from co-substrate UDP-glucuronic acid, is catalysed by members of the UDPglucuronosyltransferase (UGT) enzyme family. In humans, there are at least 20 members of the UGT enzyme family belonging to 4 different sub-families: 1A (where 9 enzymes are produced from a single gene), 2A, 2B and 3A. This diversity of UGTs facilitates glucuronidation of a vast array of chemical structures at several different functional groups, including phenols, alcohols, carboxylic acids and amines as well as rare examples of glucuronidation at carbon and sulfur atoms (Burchell and Coughtrie, 1989; Tukey and Strassburg, 2000) .
Adverse drug reactions (ADR) are a major cause of morbidity and mortality. A recent survey (Pirmohamed et al., 2004) estimated that ADRs accounted for 6.5% of hospital admissions, with a financial burden to the UK health service of £0.5 billion per annum. It is increasingly clear that glucuronidation plays a significant role in individual response to drugs, and therefore in susceptibility to ADRs. For instance, treatment-limiting toxicity of the anticancer drug irinotecan is associated with mutations in UGT1A1 (Nagar and Remmel, 2006; Hoskins et al., 2007) and a UGT1A haplotype involving mutations in UGT1A1, UGT1A3 and UGT1A7 predisposes to jaundice associated with atazanavir treatment (Lankisch et al., 2006) . There is therefore considerable interindividual and inter-tissue variation in the expression of many UGTs, e.g. (Strassburg et al., 2000; Izukawa et al., 2009) , which have significant functional sequelae (Wells et al., 2004) . Most studies aimed at determining expression levels of UGTs have relied upon mRNA measurements (often as [glucuronosyl- 14 C] (>6.7GBq/mmol) was purchased from PerkinElmer, Cambridge, UK.
Multiple antigenic peptides were synthesised by Alta Bioscience, Birmingham, UK. Antigoat IgG conjugated to horseradish peroxidase was from Sigma-Aldrich, Gillingham, UK.
All other reagents were from commonly used local suppliers.
Tissue Samples and Preparation of Microsomal Fractions.
Human liver samples used in this study have been described previously (Thomas and Coughtrie, 2003; Riches et al., 2007; Riches et al., 2009b) . Human kidney samples were obtained from the UK Human Tissue Bank, Leicester, UK. Ethical approval for local use of samples was obtained from the Tayside Research Ethics Committee. Frozen tissue was weighed and kept on ice, and 5ml of SHM buffer (250mM sucrose, 10mM HEPES, 3mM 2-mercaptoethanol, pH7.4) were added for every gram of tissue. Homogenates were prepared in a Teflon-glass homogeniser, and subjected to differential centrifugation at 10,000 x g for 15 minutes with the resulting supernatant centrifuged at 100,000 x g for 1 hour. The pellet, representing the microsomal fraction, was resuspended in 1ml per gram of original tissue used and homogenised by hand then aliquoted, snap frozen in liquid nitrogen and stored at -80°C until use (usually within 6 months).
Production of Antibodies against UGT1A1 and UGT1A6. For UGT1A1, we selected a unique 19 amino acid sequence (ENDSFLQRVIKTYKKIKKD) from the variable N-terminal region for synthesis as a multiple antigenic peptide (MAP). For UGT1A6, a 100 amino acid peptide (from Pro61 to Ala160) was selected from within the N-terminal variable region on the basis of predicted antigenicity and sequence divergence from its nearest relatives.
Antigenicity was assessed using a web based application (http://www.bioinformatics.org/JaMBW/3/1/7/), and amino acid sequence similarity was determined by alignment of all the UGT1A family members using ClustalW (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequence coding for this peptide was cloned into pET-15b with a C-terminal 6-histidine tag to facilitate purification and expressed in E.
coli BL21 (λDE3) cells following induction with IPTG. Briefly, the selected region for UGT1A6 was amplified using the following primers: 1A6VF PCR -5'
CATATGCCATGGCCTGAAGTTAATTTGCTTTTGAAA and 1A6VR PCR -5'
CTCGAGTCAAGCCAGGATCACCCCACAGGGTAA. The PCR was performed using the pET-20b/pelB-UGT1A6 vector (see below) as template and Pfu polymerase (Promega). The PCR product was cloned into pGEM-T easy (Promega) and sequenced, then excised with
NdeI and XhoI and ligated with similarly digested pET-15b to produce an N-terminal His6 tagged peptide of 1A6 corresponding to the region Pro61 to Ala160. The expressed peptide was found in the pellet after centrifugation at 12,000 x g, suggesting it was localised in inclusion bodies. Cells were harvested and the pellet resuspended in denaturing extraction buffer (50mM sodium phosphate, pH7, 300mM NaCl and 6M guanidine-HCl) and incubated on ice for 4 hours with gentle shaking. The extract was centrifuged at 12,000 x g for 20 minutes at 4°C to pellet insoluble material. 1ml of the supernatant was applied to a TALON® cobalt affinity spin column (Clontech, Saint-Germain-en-Laye, France) as described by the manufacturer. A total of 3ml of extract were passed through spin columns, and the eluant pooled and dialysed against 500 volumes of 45mM sodium phosphate pH7, 150mM NaCl, 20% (v/v) glycerol. This procedure produced a total of 9mg of purified fusion peptide. 
Expression of UGT-S•tag Fusion Protein.
A PCR product representing part of the conserved C terminal domain of the UGT1A family plus the S•tag sequence was generated using Pfu polymerase and cloned into pGEM-T easy. After sequence confirmation, the PCR product was subcloned into existing E. coli expression constructs, pET-20b/pelB-UGT1A1
and pET-20b/pelB-UGT1A6, which contain the pelB leader sequence (which targets the protein to the bacterial periplasm (Better et al., 1988; Skerra and Pluckthun, 1988)) substituted for the natural N-terminal UGT signal sequence (Ouzzine et al., 1994) . Briefly, three primers were designed to bind in the constant region of the UGT1A (UGT1A(S)F); to link the UGT1A sequence to the S-tag sequence (UGT1A(S) Linker) and as an S-tag reverse (S-tag R). The sequences of these primers were: UGT1A(S)F: 5' ACCTGGTACCAGTACCATTCCTTG 3' -this binds across a unique internal restriction endonuclease site (KpnI) noted in italics. UGT1A(S) Linker: 5'
AAATCCAAGACCCATAAAGAAACCGCTGCTGCT 3' -this comprises the last 15 nucleotides of the UGT1A constant region before the stop codon (noted in italics) and the first 18 nucleotides of the S-tag sequence. S-tagR:
5'CTCGAGGCGGCCGCCTAGCTGTCCATGTGCTG 3' -this comprises the final 15 nucleotides of the S-tag sequence, a stop codon and restriction endonuclease sites, NotI and XhoI. The cloning strategy comprised a two stage PCR. In the first stage a small PCR product of 74bp is produced using the UGT1A(S) Linker and S-tag R primers and pET-32b as template. In the second stage the purified product from the first PCR is used alongside pET-20b/pelB-UGT1A6 as the template, using the primers UGT1A(S) F and S-tag R. In the second PCR the product was expected to be 217bp. The PCR product was purified and sequenced. It was digested with KpnI and XhoI and ligated with similarly digested pET-20B/pelB-UGT1A1 or 1A6 to produce an S-tag version of these UGT isoforms. The modified expression constructs were transformed into the E. coli expression strain BL21 (λDE3). For expression of UGT1A1(S), a 500ml culture of modified terrific broth was inoculated from a small starter culture. The cells were incubated for 16 hours at 37°C with no induction. Subcellular fractionation was performed and the membrane pellet was resuspended in TSE buffer (50mM tris-acetate pH7.6, 250mM sucrose, 0.25mM EDTA).
Expression of UGT1A1(S) was confirmed using the S•tag rapid assay kit as described by the manufacturer (Merck), and by immunoblotting with peroxidase-conjugated S•protein and anti-UGT1A1 antibody. For expression of UGT1A6(S) a starter culture was used to inoculate 500ml LB with ampicillin selection. The culture was incubated until the optical density was 0.57. After adding IPTG (1mM) to induce expression the culture was incubated at 27°C for 2 hours. The membrane pellet was prepared, and expression confirmed, as for
UGT1A1(S).
Quantitative Immunoblot Analysis. Crude IgG fractions of antisera were prepared by 50% ammonium sulfate precipitation followed by extensive dialysis against PBS. For anti-UGT1A1, the best immunoblotting results were obtained by using affinity purified IgG which was prepared using the same peptide as for immunization, as described by the manufacturer (Alta Bioscience). IgG prepared from both antisera was used at a concentration of 10μg/ml for immunoblotting.
Proteins were resolved on denaturing SDS-PAGE gels (10% acrylamide monomer) and transferred electrophoretically for 16 hours at 27V to PVDF membranes (Immobilon-P, Millipore, Watford, UK) as described by Towbin et al. (Towbin et al., 1979 TBS-T and then exposed to the anti-goat IgG-peroxidase conjugate, diluted at 1:20,000 in blocking buffer, for 2 hours. After extensive washing in TBS-T, blots were developed using Western Lightning (PerkinElmer) and ECL Hyperfilm (GE Healthcare, Little Chalfont, UK).
Standard curves for quantification were generated using samples of UGT(S) loaded in a range between 0.25ng and 5 ng UGT(S).
Scans of the developed x-ray films were made using a desktop scanner attached to a personal computer, and analysed using Quantiscan 3.1 (Biosoft, Cambridge, UK) as described previously (Riches et al., 2009a) . Following pilot experiments, the quantity of microsomal protein loaded onto the gels was adjusted such that the densities of resulting bands were within the linear region of the standard curves on each blot. Each sample was analyzed on at least three separate blots with each antibody, and thus individual data points quoted are the means of these determinations.
Assay of UGT Activity. UGT1A1 activity was assayed with bilirubin as substrate using a method described previously (Heirwegh et al., 1972) , and UGT1A6 activity was assessed using 500µM 1-naphthol by the universal HPLC assay method described by Ethell et al. (Ethell et al., 1998; Taskinen et al., 2003) .
Total protein concentration analysis. Quantification of total protein levels in microsomal samples and recombinant protein preparations was carried out using the method originally described by Lowry et al. (Lowry et al., 1951) , using BSA as standard.
Results
We sought to develop a method that would overcome the problems posed by the lack of availability of purified UGT standards and facilitate the absolute immunoquantification of UGT expression in human tissue microsomes. The S-peptide/S-protein system provides a convenient mechanism for producing quantified protein standards, and is readily applicable to membrane proteins such as UGTs since it does not rely upon purifying the protein from the expression system. The functional ribonuclease activity was reconstituted when incubating the recombinant E. coli membrane fraction containing the UGT/S•tag™ fusion protein with purified S-protein (the binding is of very high affinity -K d = 10 -9 M), and the enzymatic breakdown of the substrate polycytidylic acid (poly(C)) was readily followed by measuring A 280 . By comparison with results obtained with a known S-peptide standard, the molar concentration of UGT in the extract was determined. We used expression constructs generated with the pelB leader sequence to target the UGT expression to the periplasmic membrane, since full-length UGTs are normally expressed in inclusion bodies in E. coli and require harsh conditions to solubilise them.
Antibodies against UGT1A1 and UGT1A6. We designed two peptides which were used to generate isoform-specific antibodies against human UGT1A1 and UGT1A6 in sheep. For UGT1A1, we chose a short region in the N-terminal variable region which was synthesized as a MAP, and for UGT1A6 a 100-amino acid peptide was expressed in E. coli as a fusion protein with a 6xHis tag and purified by affinity chromatography. We tested the specificity of the antibodies produced using immunoblot analysis against recombinant human UGTs as shown in Figure 1 .
To validate the immunoquantification method, we chose to quantify the expression of UGTs 1A1 and 1A6 in microsomes prepared from 29 individual human liver samples. For each liver sample and antibody, conditions were optimized in order that the bands were within the linear range of the standard curves generated using the S•tag™-labelled UGTs. A representative immunoblot for each antibody is shown in Figure 2 .
UGT1A1 and UGT1A6 Expression in Human Tissues. There was considerable variation in the expression of UGTs 1A1 and 1A6 in the various liver samples (Table 2 and although expression could be detected in each sample. The quantity of UGT1A1 found in these liver samples varied from 0.04 µg/g tissue to 1.14 µg/g tissue, a 28-fold variation, with a mean of 0.34 µg/g tissue. There is a common variable number tandem repeat (VNTR) polymorphism in the TATA box of the UGT1A1 gene (UGT1A1*28) that is associated with the reduced expression of UGT1A1, reduced glucuronidation of bilirubin and mild unconjugated hyperbilirubinemia seen in Gilbert's syndrome (Bosma et al., 1995; Monaghan et al., 1996) , which presumably accounts for a significant proportion of the variability seen here. UGT1A1 expression was not detected in microsomes prepared from the human kidney samples.
With the expression of UGT1A6 we again observed extensive variation in levels within liver microsomal samples, ranging from 0.07 to 1.42 µg/g tissue (one sample had no detectable expression) with a mean of 1.18 -a 20 fold variation in the amount of UGT1A6.
Expression of UGT1A6 was observed in microsomal samples prepared from human kidney, although this was approximately 3-fold lower than in the liver.
To confirm that expression levels measured with this assay were representative of enzyme function, we carried out assays for UGT activity using the hepatic microsomal samples. We used bilirubin as a probe substrate for UGT1A1 and 1-naphthol (at a concentration of 500µM) as a probe substrate for UGT1A6, and performed correlation analysis between the protein expression and enzyme activity datasets. The results are presented in Table 1 and Figure 4 . There was a strong correlation between UGT1A1 expression and bilirubin UGT activity in the human liver microsomes (Pearson's r = 0.82, p < 0.0001) and a somewhat lower, but still significant, degree of correlation between UGT1A6 protein expression and the glucuronidation of 500µM 1-naphthtol (Pearson's r = 0.61, p < 0.005).
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Discussion
The ability to reliably predict the contribution of individual drug metabolising enzymes to the in vivo fate of xenobiotics would be of considerable value and benefit to chemical and pharmaceutical industries, as well as the regulatory bodies that oversee them. For many conjugating enzyme families, including the UGTs, we still do not have a good idea of the relative contributions of the major isoforms in this regard, not least because of the lack of reliable methods for quantifying protein expression. This is mainly due to the fact that UGTs are integral membrane proteins that are difficult to express and purify from e.g. E. coli, which means it is extremely challenging to produce accurately and absolutely quantified protein for the generation of standard curves for immunoquantification approaches. Another drawback is the lack of high quality, isoform specific antibodies for immunoquantification.
Here we have described a novel approach to the immunoquantification of UGT protein expression in human tissues. The method, which uses expressed and readily quantified UGT/S•tag™ fusion proteins to generate standard curves, was validated using two important human UGTs, UGT1A1 and UGT1A6, against which we also produced new isoform-specific antibodies.
The UGT/S•tag™ fusion proteins with the pelB leader sequence were expressed in E.
coli and were found in the membrane fraction upon ultracentrifugation, indicating that they had been correctly targeted to the periplasm. When combined with an excess of S-protein, they formed an active ribonuclease activity that was readily quantified spectrophotometrically using the S•tag rapid assay. These proteins were then successfully used to develop standard curves for quantification of UGT protein levels by immunoblotting.
Because of its role in the detoxification and elimination of bilirubin, UGT1A1 is considered one of the most important (if not the most important) UGTs, and is expressed primarily in the liver and to a lesser extent in the gastrointestinal tract (Ohno and Nakajin, This article has not been copyedited and formatted. The final version may differ from this version. (Chen et al., 2007) . We noticed that there is a reasonable similarity in the expression profiles of UGT1A1 and UGT1A6 in this set of liver samples. We know from Figure 1 that there is no evidence for any significant cross-reactivity of these two new antibodies, so the possibility remains that there is a degree of co-ordinate regulation of these two UGTs.
The method reported here for producing recombinant protein standards as S•tag™ fusion proteins is readily applicable to potentially any recombinant protein expression system, particularly where proteins such as membrane proteins are difficult to purify, and we In summary, we have devised a novel approach to the immunoquantification of UGT expression in human tissue samples. The method is straightforward to establish and is broadly applicable, and provides the opportunity to determine the relative contributions of different UGT isoforms to the metabolism of drugs and other xenobiotics.
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BLQ, below limit of quantification
